Citi Pharma Maintains Steady Profit in 1QFY26 Despite Rising Financial Costs
Citi Pharma Limited posted a profit after tax of Rs203.69 million for 1QFY26, marking a 1% rise from last year. While higher finance costs and reduced other income pressured margins, improved gross profit and lower taxation helped sustain steady earnings.
JS Bank Reports 52% Decline in 9MFY25 Profit to Rs6.09 Billion Amid Rising Costs and Lower Income
JS Bank Limited (PSX: JSBL) has reported a 52% year-on-year decline in profit for the nine months ended September 30, 2025, to Rs6.09 billion. The fall in earnings was driven by a contraction in net interest income and a sharp rise in operating expenses, despite gains from securities and higher fee-based revenues.
Bank Alfalah Declares 75% Dividend Despite 39% Drop in Profit for 9MFY25
Bank Alfalah Limited reported a 39% drop in profit for the nine months ended September 30, 2025, but declared a 75% cumulative dividend payout. The results reflect margin compression, higher provisioning, and rising costs, yet highlight the bank’s resilience and commitment to rewarding shareholders amid economic challenges.
Engro Fertilizers Reports 21% Profit Decline in 9MFY25 Amid Lower Sales and Higher Finance Costs
Engro Fertilizers Limited reported a 21% decline in profit after tax for 9MFY25, driven by lower sales and rising finance costs, despite improved gross margins and controlled operational expenses.